open access
Ruthenium coordination compounds as drugs in modern anticancer therapy
open access
Abstract
The study of metal coordination compounds for the treatment of cancer has resulted in the identification of some unique properties of ruthenium complexes as antitumour agents. Among these group two of them, NAMI-A and KP1019 have entered the clinical trials with patients. The studies showed that NAMI-A inhibits the formation of metastases and KP1019 demonstrates exciting anticancer activities especially in colorectal carcinoma. As well as these two compounds, organometallic ruthenium-based complexes RM175, RAPTA-T, RDC11 and DW1/2 are very promising in the antitumour therapy.
Abstract
The study of metal coordination compounds for the treatment of cancer has resulted in the identification of some unique properties of ruthenium complexes as antitumour agents. Among these group two of them, NAMI-A and KP1019 have entered the clinical trials with patients. The studies showed that NAMI-A inhibits the formation of metastases and KP1019 demonstrates exciting anticancer activities especially in colorectal carcinoma. As well as these two compounds, organometallic ruthenium-based complexes RM175, RAPTA-T, RDC11 and DW1/2 are very promising in the antitumour therapy.
About this articleTitle
Ruthenium coordination compounds as drugs in modern anticancer therapy
Journal
Nowotwory. Journal of Oncology
Issue
Article type
Review paper
Pages
517-528
Published online
2016-02-05
Page views
1485
Article views/downloads
7230
DOI
10.5603/NJO.2015.0107
Bibliographic record
Nowotwory. Journal of Oncology 2015;65(6):517-528.
Authors
Urszula Śliwińska-Hill
Joanna Celmer